Abstract:<div class="abstract-group"> <section class="article-section article-section__abstract" lang="en" data-lang="en" id="section-1-en"> <h3 class="article-section__header main abstractlang_en main">Abstract</h3> <div class="article-section__content en main"> <p>Calcium‐activated chloride channels (CaCCs) are ion channels with key roles in physiological processes. They are abnormally expressed in various cancers, including esophageal squamous cell cancer, head and neck squamous cell carcinoma, colorectal cancer, and gastrointestinal stromal tumors. The CaCC component TMEM16A/ANO1 was recently shown to be overexpressed in lung adenocarcinoma cells and may serve as a tumorigenic protein. In this study, we determined that matrine is a potent TMEM16A inhibitor that exerts anti‐lung adenocarcinoma effects. Patch clamp experiments showed that matrine inhibited TMEM16A current in a concentration‐dependent manner with an IC<sub>50</sub> of 27.94 ± 4.78 μM. Molecular simulation and site‐directed mutation experiments demonstrated that the matrine‐sensitive sites of the TMEM16A channel involve the amino acids Y355, F411, and F415. Results of cell viability and wound healing assays showed that matrine significantly inhibited the proliferation and migration of LA795 cells, which exhibit high TMEM16A expression. In contrast, matrine has only weak inhibitory effect on CCD‐19Lu and HeLa cells lacking TMEM16A expression. Matrine‐induced effects on the proliferation and migration of LA795 cells were abrogated upon shRNA‐mediated TMEM16A knockdown in LA795 cells. Finally, in vivo experiments demonstrated that matrine dramatically inhibited the growth of lung adenocarcinoma xenograft tumors in mice but did not affect mouse body weight. Collectively, these data indicate that matrine is an effective and safe TMEM16A inhibitor and that TMEM16A is the target of matrine anti‐lung adenocarcinoma activity. These findings provide new insight for the development of novel treatments for lung adenocarcinoma. </p>

Inhibition of TMEM16A Ca2+-activated Cl- channels by avermectins is essential for their anticancer effects

Anti-TMEM16A Monoclonal Antibody Inhibits the Growth and Metastasis of Esophageal Squamous Cell Carcinoma

Inhibitory effect of matrine on the in vitro invasiveness of human malignant melanoma cell line A375

Research progress of avermectins in anti-tumor

Matrine Inhibits Invasiveness and Metastasis of Human Malignant Melanoma Cell Line A375 in Vitro

Matrine is a novel inhibitor of the TMEM16A chloride channel with antilung adenocarcinoma effects

Inhibition of TMEM16A expression suppresses growth and invasion in human colorectal cancer cells.

Cytotoxic Effects of Avermectin on Human HepG2 Cells in Vitro Bioassays.

Avermectin Confers Its Cytotoxic Effects by Inducing DNA Damage and Mitochondria-Associated Apoptosis

Three Sesquiterpene Lactones Suppress Lung Adenocarcinoma by Blocking TMEM16A-mediated Ca2+-activated Cl- Channels.

Benzophenanthridine alkaloids suppress lung adenocarcinoma by blocking TMEM16A Ca2+-activated Cl- channels

Inhibition of Human Cancer Cell Growth by Analogues of Antimycin A.

&Lt;p>progress in Understanding the Molecular Mechanisms Underlying the Antitumour Effects of Ivermectin</p>

Actinomycin V Inhibits Migration and Invasion via Suppressing Snail/Slug-Mediated Epithelial-Mesenchymal Transition Progression in Human Breast Cancer MDA-MB-231 Cells In Vitro.

Aloe-Emodin Induces Breast Tumor Cell Apoptosis Through Upregulation of Mir-15A/mir-16-1 That Suppresses BCL2

Identification Of The Novel Tmem16a Inhibitor Dehydroandrographolide And Its Anticancer Activity On Sw620 Cells

TMEM16A ion channel: A novel target for cancer treatment

Avermectin induces toxic effects in insect nontarget cells involves DNA damage and its associated programmed cell death

Avermectin B1 mediates antitumor activity and induces autophagy in osteosarcoma through the AMPK/ULK1 signaling pathway

A Novel Antimycin Analogue Antimycin A2c, Derived from Marine Streptomyces Sp., Suppresses HeLa Cells Via Disrupting Mitochondrial Function and Depleting HPV Oncoproteins E6/E7.

Co-targeting TMEM16A with a Novel Monoclonal Antibody and EGFR with Cetuximab Inhibits the Growth and Metastasis of Esophageal Squamous Cell Carcinoma.